3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
24
Lymphoma, Non-Hodgkin
17
Lymphoma, Follicular
14
Lymphoma, Mantle-Cell
9
Lymphoma
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
2
Leukemia
2
Hematologic Diseases
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, B-Cell
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Interventions
liposomal amphotericin B
2
Rituximab
2
Levofloxacin
2
Gemcitabine
2
Early Intervention, Educational
2
Doxorubicin
2
Darbepoetin alfa
2
ferrous sulfate
1
ferric gluconate
1
duvelisib
1
belinostat
1
Vincristine
1
VAP-cyclo protocol
1
Sucrose
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Prednisone
1
Pharmacogenomic Testing
1
Ondansetron
1
Morphine
1
Ketamine
1
Hypericum extract LI 160
1
Filgrastim
1
Fentanyl
1
Epoetin Alfa
1
Drug Therapy
1
Dextromethorphan
1
Dexamethasone
1
Dalteparin
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Immunoblastic Lymphadenopathy
×
Bendamustine Hydrochloride
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled